Soleus Capital Management L.P. Sells 49,500 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Soleus Capital Management L.P. reduced its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 52.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 45,500 shares of the company's stock after selling 49,500 shares during the quarter. Soleus Capital Management L.P. owned 0.06% of Viridian Therapeutics worth $872,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of VRDN. Loomis Sayles & Co. L P acquired a new stake in shares of Viridian Therapeutics during the 4th quarter worth $26,845,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Viridian Therapeutics by 2,847.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,326,811 shares of the company's stock worth $25,436,000 after purchasing an additional 1,281,799 shares in the last quarter. Deep Track Capital LP grew its holdings in shares of Viridian Therapeutics by 20.6% during the 4th quarter. Deep Track Capital LP now owns 4,522,741 shares of the company's stock worth $86,701,000 after purchasing an additional 771,796 shares in the last quarter. FMR LLC grew its holdings in shares of Viridian Therapeutics by 6.2% during the 4th quarter. FMR LLC now owns 11,881,912 shares of the company's stock worth $227,776,000 after purchasing an additional 698,434 shares in the last quarter. Finally, Parkman Healthcare Partners LLC boosted its stake in Viridian Therapeutics by 155.9% in the fourth quarter. Parkman Healthcare Partners LLC now owns 1,087,634 shares of the company's stock valued at $20,850,000 after buying an additional 662,634 shares in the last quarter.

Viridian Therapeutics Trading Down 0.7%

Shares of VRDN stock traded down $0.10 during mid-day trading on Friday, reaching $13.57. 645,430 shares of the stock traded hands, compared to its average volume of 1,191,100. The stock's fifty day simple moving average is $13.17 and its two-hundred day simple moving average is $16.86. Viridian Therapeutics, Inc. has a 1-year low of $9.90 and a 1-year high of $27.20. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -3.15 and a beta of 0.57. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, beating analysts' consensus estimates of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The firm had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.16 million. Viridian Therapeutics's revenue was up .0% compared to the same quarter last year. On average, research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Analyst Ratings Changes

VRDN has been the topic of several research analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $36.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday. The Goldman Sachs Group reduced their price objective on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. JMP Securities reduced their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Finally, Royal Bank of Canada reduced their price objective on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, Viridian Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $36.70.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.